Document is current
Any future updates will be listed below
-
Authors
Washington, Charles III
Dapas, Matthew
Biddanda, Arjun
Magnaye, Kevin M.
Aneas, Ivy
Helling, Britney A.
Szczesny, Brooke
Boorgula, Meher Preethi
Taub, Margaret A.
Kenny, Eimear
Mathias, Rasika A.
Barnes, Kathleen C.
,
Campbell, Monica
Figueiredo, Camila
Hansel, Nadia N.
Ober, Carole
Olopade, Christopher O.
Rotimi, Charles N.
Watson, Harold
Khurana Hershey, Gurjit K.
Kercsmar, Carolyn M.
Gereige, Jessica D.
Makhija, Melanie
Gruchalla, Rebecca S.
Gill, Michelle A.
Liu, Andrew H.
Rastogi, Deepa
Busse, William
Gergen, Peter J.
Visness, Cynthia M.
Gold, Diane R.
Hartert, Tina
Johnson, Christine C.
Lemanske, Robert F. Jr.
Martinez, Fernando D.
Miller, Rachel L.
Ownby, Dennis
Seroogy, Christine M.
Wright, Anne L.
Zoratti, Edward M.
Bacharier, Leonard B.
Kattan, Meyer
O’Connor, George T.
Wood, Robert A.
Nobrega, Marcelo A.
Altman, Matthew C.
Jackson, Daniel J.
Gern, James E.
McKennan, Christopher G.
Ober, Carole https://orcid.org/0000-0003-4626-9809
-
Funding
Funding for this research was provided by:
HHMI Gilliam Fellowship (GT10892)
NIH (TL1 TR002388, F31 HL143891, UL1 TR001079, R01 HL104608, UL1 RR025780, UL1 TR000154, UL1 TR000077, UL1 TR000077, UL1 TR000451, UL1 TR001105, UL1 TR000451, UL1 TR001105, UL1 TR000075, UM2 Al117870, HHSN272201000052l, UL1 TR001430, UM1 Al160040, UL1 TR000040, UM1 Al114271, UM1 Al60040, UM1 Al114271, 5UH3OD023282, U19 Al095230, UL1 TR000150, R01 HL104608, R01 HL104608, R01 HL104608, R01 HL104608)
NIAID (HHSN272200900052C)
- License Information
-
More Information
Article History
Received: 15 April 2022
Accepted: 15 September 2022
First Online: 29 September 2022
Declarations
:
: The included studies were approved by the IRBs at each participating center: EVE/UChicago IRB #6626; CAG/UChicago IRB #6626 and #153651A; URECA (Central IRB at University of Wisconsin and WIRB IRB # 20142570); APIC/Johns Hopkins IRB #5; APIC/Boston University Medical Center (Blue Panel IRB); APIC/Children’s Memorial Medical Center IRB #2011-14581; APIC/Cincinnati Children’s Hospital IRB; APIC/University of Texas Southwestern Medical School IRB #8843; APIC/National Jewish Health IRB; APIC/Henry Ford Health System IRB #6782; APIC/Columbia University Medical Center IRB #1; APIC/Children’s National Medical Center IRB. APIC&URECA/UChicago IRB #19-0046. Consent was obtained by the parents of children in the cohorts and by participants who were age 18 years of age or older. Assent was obtained from older children who were under the age of 18 years. All research conformed to the Declaration of Helsinki.
: Not applicable.
: K.C.B. is employed by Tempus Labs. G.K.K.H. reports grants from Adare during the conduct of the study. C.M.K. received royalties from editing chapter on treatment of acute asthma. E.M.Z. has served on the DSMB for another researcher’s grant investigating asthma at Wayne State University. L.B.B. reports personal fees from GlaxoSmithKline Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi/Regeneron, Vectura, Circassia, Elsevier, Kinaset, and Vertex outside the submitted work. G.T.O. has received consulting fees from AstraZeneca related to the development of new medications for asthma and COPD and a grant from Janssen. Pharmaceutical related to pathogenetic mechanisms of COPD. R.A.W. has received grants from Aimmune, Astellas, DBV, Genentech, Novartis, Regeneron, and Sanofi. M.C.A. has received consulting fees from Regeneron outside the submitted work. D.J.J. reports grants and personal fees from GlaxoSmithKline and personal fees from Novartis, Pfizer, Sanofi, Regeneron, AstraZeneca, and Vifor Pharma, outside the submitted work. J.E.G. is a paid consultant for AstraZeneca, Meissa Vaccines Inc. and Gossamer Bio, and has stock options in Meissa Vaccines Inc. The remaining authors declare that they have no competing interests.
